{
    "sponsor_name": "",
    "study_acronym": "",
    "tested_imp": "",
    "comparative_drug": "",
    "study_type": "",
    "interventional_study_phase": "",
    "study_design": "",
    "aim_of_study": "",
    "target_disease": "",
    "type_of_randomization": "",
    "randomization_stratification": [],
    "apixaban_dosing": "",
    "dalteparin_dosing": "",
    "apixaban_supply_form": "",
    "dalteparin_supply_form": "",
    "scheduled_visits": [],
    "primary_efficacy_outcome": "Incidence of the first event of the composite of objectively confirmed recurrent Venous Thromboembolism (VTE) or VTE-related death during the study period. This includes proximal DVT of the lower limbs (symptomatic or unsuspected), symptomatic DVT of the upper limb, pulmonary embolism (symptomatic or unsuspected), and VTE-related death.",
    "secondary_efficacy_outcomes": [],
    "primary_safety_outcome": "Incidence of major bleeding, as defined by the International Society on Thrombosis and Haemostasis (ISTH) guidelines.",
    "secondary_safety_outcomes": [],
    "maximum_sample_size_per_arm": 0,
    "recommended_inclusion_criteria": [],
    "recommended_exclusion_criteria": []
}